Mele et al. reported that lapatinib, a tyrosine kinase inhibitor widely used for the treatment of breast cancer, and polydatin, a G6PD inhibitor, exerted a synergic effect on MCF7 (MCF7mock) cell viability, but had no effect on G6PD-overexpressing MCF7 (MCF7G6PD+) cells [76]. The gene discussed is G6PD; the disease is breast cancer.